AGF39: Cytokine Composition and Clinical Application in CytoMesopecia
In Part 1, we examined the biological foundation of cytokines and their strategic importance in modern alopecia management.
In this second installment, we focus on AGF39, AesMed’s proprietary cytokine solution, and explain how its composition and application protocol operationalize the concept of CytoMesopecia – Cytokines Mesotherapy for Alopecia.
1. AGF39: A Cytokine Architecture Designed for Alopecia
AGF39 is not a generic growth-factor mixture. It is a cytokine-structured formulation designed specifically to address the biological mechanisms underlying hair loss.
Rather than overstimulating follicles, AGF39 aims to restore signaling balance within the follicular microenvironment, supporting regeneration, vascularization, and anagen maintenance.
2. Key Cytokines and Growth Factors in AGF39
AGF39 contains a strategically selected panel of cytokines and bioactive factors, each playing a defined role in hair follicle biology:
FGF9 (Fibroblast Growth Factor 9)
- Induces dermal Wnt signaling activation
- Promotes hair follicle regeneration, particularly in wound-related environments
- Supports feedback loops necessary for new follicle formation
KGF (Keratinocyte Growth Factor)
- Regulates keratinocyte growth and differentiation
- Protects keratinocytes from UVA/UVB and chemotherapy-related damage
- Supports new hair formation and follicular survival
IGF-1 (Insulin-like Growth Factor-1)
- Acts as a growth hormone mediator
- Stimulates angiogenesis and keratinocyte proliferation
- Plays a critical role in anagen phase maintenance
VEGF (Vascular Endothelial Growth Factor)
- Enhances angiogenesis and vascular maintenance
- Increases perifollicular blood vessel density and diameter
- Improves nutrient and oxygen delivery to follicles
bFGF (basic Fibroblast Growth Factor)
- Activates dermal papilla cells
- Stimulates collagen and elastin synthesis
- Supports follicular structural integrity and hair growth signaling
Noggin (BMP Antagonist)
- Inhibits BMP and DKK-1 signaling pathways
- Activates Wnt signaling essential for anagen induction
- Contributes to new follicle formation and growth phase entry
Cu/Zn SOD (Superoxide Dismutase)
- Protects hair follicles from oxidative stress
- Reduces cellular damage caused by reactive oxygen species (ROS)
- Supports a favorable environment for sustained hair growth
Together, these components form a biologically coordinated signaling network, rather than acting as isolated stimulants.
3. Application Concept: How AGF39 Is Used in CytoMesopecia
AGF39 is applied within the CytoMesopecia – Cytokines Mesotherapy for Alopecia framework, emphasizing targeted dermal delivery and microenvironment control.
Delivery Method
- Administered via mesotherapy-based protocols
- Delivered directly into the scalp dermis, where hair follicles reside
- Ensures high local bioavailability while minimizing systemic exposure
Therapeutic Objectives
- Normalize follicular signaling pathways
- Modulate chronic micro-inflammation
- Support angiogenesis and dermal vitality
- Extend the anagen phase and stabilize follicular activity
Clinical Positioning
AGF39 is designed as a platform therapy, allowing seamless integration with:
- PRP and autologous treatments
- Pharmacological therapies
- Device-based scalp treatments
- Post-hair-transplant maintenance programs
This makes CytoMesopecia adaptable to diverse clinical strategies and patient profiles.
4. Strategic Value for Clinics and Industry Partners
From a professional and commercial perspective, AGF39 offers:
For Medical Professionals
- A scientifically grounded cytokine protocol
- Clear differentiation from conventional growth-factor treatments
- Structured, reproducible clinical application
- Alignment with regenerative medicine trends
For Industry & Distribution Partners
- Strong conceptual branding under CytoMesopecia
- High educational value for professional marketing
- Scalable positioning across global markets
- Long-term relevance beyond short-term treatment trends
5. CytoMesopecia as a New Standard in Alopecia Care
AesMed positions CytoMesopecia – Cytokines Mesotherapy for Alopecia as a next-generation treatment framework, shifting alopecia management from suppression-based strategies to biological regulation and regeneration.
AGF39 is the practical embodiment of this philosophy – translating cytokine science into clinically applicable and commercially sustainable solutions.
Conclusion
By combining a carefully engineered cytokine composition with targeted mesotherapy delivery, AGF39 redefines how cytokine science is applied in alopecia treatment.
For clinicians, industry professionals, and distribution partners, CytoMesopecia represents not just a treatment option, but a strategic framework for the future of professional hair loss care.
About AesMed
AesMed specializes in cytokine-based alopecia solutions, developing professional-grade technologies grounded in regenerative biology.
Through innovations such as AGF39 and the CytoMesopecia framework, AesMed supports global partners in advancing science-driven hair restoration.
Learn more: www.aesmed.co.kr
